Figures & data
Table 1. Clinical characteristics and outcomes of 50 patients with anticholinergic delirium, who were treated by transdermal or oral rivastigmine.
Table 2. Anticholinergic agents ingested.
Figure 1. Sedation requirements in 50 patients after transdermal or oral rivastigmine administration for anticholinergic delirium.
![Figure 1. Sedation requirements in 50 patients after transdermal or oral rivastigmine administration for anticholinergic delirium.](/cms/asset/c5700f8e-5201-47a5-856f-9203e8310e74/ictx_a_2319854_f0001_c.jpg)
Table 3. Pharmacokinetic and pharmacokinetic properties of physostigmine and rivastigmine.